FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2591544462> ?p ?o ?g. }

• W2591544462 endingPage "8519" @default.
• W2591544462 startingPage "8519" @default.
• W2591544462 abstract "8519 Background: Vemurafenib (V; RG7204, PLX4032), a BRAF inhibitor, induces responses in a majority of patients (pts) with V600EBRAF mutant melanoma, but most eventually progress. We report the patterns of disease progression (PD) of pts with MM treated on the phase I study of V. Methods: Dose escalation cohort pts were treated with V 240-1,120 mg po BID, and MTD extension cohort pts with 960 mg BID. Clinical response was evaluated by RECIST every 8 weeks. Pts with PD in a disease site for which local therapy (surgery or radiotherapy) was feasible were allowed to continue on V post-progression. Survival from time of progression was estimated for pts who were and were not treated post-progression. Results: 48 pts (16 escalation, 32 extension cohort) with V600EBRAF mutation were treated. Median age 53 yrs, 27 (56%) male, 35 (73%) M1c, 27 (56%) ECOG PS of 1, and 23 (48%) had received ≥ 2 prior systemic therapies. Median OS has not been reached for all 48 pts (median follow up [F/U] was 12.5 mo (range 1.2-29.2). The common sites of PD were: Skin/soft tissue (44% of all 48 pts); nodes (27%); brain/CNS (25%); lungs (19%); liver (15%); bone, GI (10%). Among 42 pts with PD, 19 (45%) progressed only in new sites, 8 (19%) in the brain only and 11 (26%) in both new and original sites. Among 18 pts who continued PLX4032 >30 days after a local therapy of a PD lesion(s), a median OS has not been reached with a median F/U of 15.5 mo from initiation of PLX4032. Median treatment duration beyond initial PD was 3.6 mo (range, 1.1-9.9), and median OS from the time of initial PD has not been reached (median F/U 6.0 mo). For pts who did not continue treatment after PD, median OS from the time of PD was 1.4 mo. Adverse events during continued dosing in these pts were similar to those observed before PD. Conclusions: For subset of pts with PD in limited sites, continuation of PLX4032 treatment beyond PD is potentially beneficial after a local therapy. Further study of the impact of post-progression treatment is warranted while mechanisms of resistance and novel agents for MM are emerging. Median (mo) All pts (n=48) Pts—new site PD only (n=19) Pts—existing sites PD only (n=9) Pts—both existing and new sites PD (n=11) PFS 7.0 6.7 5.3 5.4 OS Not reached 12.3 18.0 11.5 * 3 pts: symptomatic PD." @default.
• W2591544462 created "2017-03-03" @default.
• W2591544462 creator A5003636426 @default.
• W2591544462 creator A5009482043 @default.
• W2591544462 creator A5020515172 @default.
• W2591544462 creator A5023174631 @default.
• W2591544462 creator A5028866253 @default.
• W2591544462 creator A5042394839 @default.
• W2591544462 creator A5049243227 @default.
• W2591544462 creator A5056904020 @default.
• W2591544462 creator A5083745558 @default.
• W2591544462 creator A5083883593 @default.
• W2591544462 date "2011-05-20" @default.
• W2591544462 modified "2023-09-27" @default.
• W2591544462 title "Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM)." @default.
• W2591544462 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.8519" @default.
• W2591544462 hasPublicationYear "2011" @default.
• W2591544462 type Work @default.
• W2591544462 sameAs 2591544462 @default.
• W2591544462 citedByCount "27" @default.
• W2591544462 countsByYear W25915444622012 @default.
• W2591544462 countsByYear W25915444622013 @default.
• W2591544462 countsByYear W25915444622014 @default.
• W2591544462 countsByYear W25915444622015 @default.
• W2591544462 countsByYear W25915444622016 @default.
• W2591544462 countsByYear W25915444622017 @default.
• W2591544462 countsByYear W25915444622018 @default.
• W2591544462 countsByYear W25915444622019 @default.
• W2591544462 countsByYear W25915444622021 @default.
• W2591544462 countsByYear W25915444622022 @default.
• W2591544462 crossrefType "journal-article" @default.
• W2591544462 hasAuthorship W2591544462A5003636426 @default.
• W2591544462 hasAuthorship W2591544462A5009482043 @default.
• W2591544462 hasAuthorship W2591544462A5020515172 @default.
• W2591544462 hasAuthorship W2591544462A5023174631 @default.
• W2591544462 hasAuthorship W2591544462A5028866253 @default.
• W2591544462 hasAuthorship W2591544462A5042394839 @default.
• W2591544462 hasAuthorship W2591544462A5049243227 @default.
• W2591544462 hasAuthorship W2591544462A5056904020 @default.
• W2591544462 hasAuthorship W2591544462A5083745558 @default.
• W2591544462 hasAuthorship W2591544462A5083883593 @default.
• W2591544462 hasConcept C121608353 @default.
• W2591544462 hasConcept C126322002 @default.
• W2591544462 hasConcept C141071460 @default.
• W2591544462 hasConcept C143998085 @default.
• W2591544462 hasConcept C2776131300 @default.
• W2591544462 hasConcept C2777658100 @default.
• W2591544462 hasConcept C2994587330 @default.
• W2591544462 hasConcept C502942594 @default.
• W2591544462 hasConcept C509974204 @default.
• W2591544462 hasConcept C71924100 @default.
• W2591544462 hasConcept C72563966 @default.
• W2591544462 hasConcept C90924648 @default.
• W2591544462 hasConceptScore W2591544462C121608353 @default.
• W2591544462 hasConceptScore W2591544462C126322002 @default.
• W2591544462 hasConceptScore W2591544462C141071460 @default.
• W2591544462 hasConceptScore W2591544462C143998085 @default.
• W2591544462 hasConceptScore W2591544462C2776131300 @default.
• W2591544462 hasConceptScore W2591544462C2777658100 @default.
• W2591544462 hasConceptScore W2591544462C2994587330 @default.
• W2591544462 hasConceptScore W2591544462C502942594 @default.
• W2591544462 hasConceptScore W2591544462C509974204 @default.
• W2591544462 hasConceptScore W2591544462C71924100 @default.
• W2591544462 hasConceptScore W2591544462C72563966 @default.
• W2591544462 hasConceptScore W2591544462C90924648 @default.
• W2591544462 hasIssue "15_suppl" @default.
• W2591544462 hasLocation W25915444621 @default.
• W2591544462 hasOpenAccess W2591544462 @default.
• W2591544462 hasPrimaryLocation W25915444621 @default.
• W2591544462 hasRelatedWork W2011042089 @default.
• W2591544462 hasRelatedWork W2027663212 @default.
• W2591544462 hasRelatedWork W2098740023 @default.
• W2591544462 hasRelatedWork W2312265177 @default.
• W2591544462 hasRelatedWork W2347065665 @default.
• W2591544462 hasRelatedWork W2468709891 @default.
• W2591544462 hasRelatedWork W2518421251 @default.
• W2591544462 hasRelatedWork W2600125892 @default.
• W2591544462 hasRelatedWork W2977363333 @default.
• W2591544462 hasRelatedWork W2563082447 @default.
• W2591544462 hasVolume "29" @default.
• W2591544462 isParatext "false" @default.
• W2591544462 isRetracted "false" @default.
• W2591544462 magId "2591544462" @default.
• W2591544462 workType "article" @default.